Potential effects of bradykinin on myocardial capillary growth after angiotensin converting enzyme inhibition

References

• DE FREITAS FM, FARRACO EZ, DE AZEVEDO DF: Generalcirculatory alterations induced by intravenous infusion of synthetic bradykinin in man. Circulation (1964) 29:66–70.
   PubMed Web of Science ®Google Scholar
• WILLIS LR, LUDEN JH, HOOK JB, WILLIAMSON HE: Mecha-nism of-Mtltriuretic action of bradykinin Am. J. Physiot (1969) 217:-5.
   Google Scholar
• LEVINSKY NG: The renal kallikrein-kinin system. Cir.Res. (1979) 44:441–451.
   PubMed Web of Science ®Google Scholar
• ARMSTRONG D, JEPSON JB, KEELE CS, STEWART JW: Development of pain-producing substances in human plasma. Nature (1954) 174:791–792.
   PubMed Web of Science ®Google Scholar
• ARMSTONG D: Pain. Handb. Exp. Pharmacol. (1970) 25:434–481.
   Google Scholar
• SCICLI AG, MINDROOIU T, SCICLI G, CARRETERO OA:Blood kinins, their concentrations in normal subjects and in patients with congenital deficiency in plasma prekallikrein and kininogen. J. Lab. Clin. Med. (1982) 100:81–93.
   PubMedGoogle Scholar
• SHIMAMOTO K, ANDO T, TANAKA S, NAICAHASHI Y,N1SHITANI T, HOSODA S, ISHIDA H, IIMURA O: An im-proved method for the determination of human blood kinin levels by sensitive kinin radioimmunoassay. En-docrinol. Jpn. (1982) 29:487–494.
   PubMedGoogle Scholar
• FARHY RD, HO K-L, CARRETERO OA, SCICLI AG: Kininsmediate the antiproliferative effect of ratnipril in rat carotic artery. Biochem. Biophys. Res. Commun. (1992) 182:282–288.
   Google Scholar
• BECKER RHA, WEENIER G, LINZ W: Preservation of endo-thelial function by ramipril in rabbits on a long-term atherogenic diet J. Cardiovasc. Pharmacol. (1991) 18\(Suppl. 2):S110–S115.
   Google Scholar
• SCHOLKENS BA, LINZ W, KONIG W: Effects of the angiotensin converting enzyme inhibitor, ramipril, in isolated ischemic rat heart are abolished by a bradykinin antagonist./ Hypertens. (1988) 6\(Suppl. 4):25–28.
   Google Scholar
• MARTORANA PA, KETTENBACH B, BREIPOHL G, LINZ W,SCHOLKENS BA: Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist Eur. j Pharmacol (1990) 182:395–396.
   Google Scholar
• STAUSS HM, ZHU YC, REDLICH T, UNGER T: Early andlate treatment of infarction-induced heart failure with a converting enzyme inhibitor: Bradykinin potentia-tion versus angiotensin II reduction. Hypertension (1993) 22:429.
   Web of Science ®Google Scholar
• LINZ W, SCHOLKENS BA: A specific B2-bradykinin recep- tor anatagonist Hoe 140 abolishes the antihypertrophiceffect of ramipriL Br. J. Pharmacol. (1992) 105:771-772. Detailed report on the role of BK after ACE inhibition in regression of left ventricle hypertrophy.
   Google Scholar
• UNGER T, MAT 1.E.ELD T, LAMBERTY V, BOCK P, MALL G, LINZ W, SCHOLKENS BA, GOHLKE P: Effect of early-onsetangiotensin converting enzyme inhibition on myocar-dial capillaries. Hypertension (1992) 20:478–482.
   Google Scholar
• Detailed report on potential effects of BK on capillary growth after treatment with ramipril in a sub-antihypertensive dose in SHR.
   Google Scholar
• MALL G, ZIMMER G, BADEN S, MA! IFELD T: Capillary neoformation in the rat heart - stereological studies on papillary muscles in hypertrophy and physiologic heart. Basic Res. Cardiol. (1990) 85:531–540.
   PubMed Web of Science ®Google Scholar
• Detailed report on myocardial proliferation after improving capillary blood flow.
   Google Scholar
• CARRETERO OA, SCICLI AG: Kinins paracrine hormone. Kidney Int. (1998) 34:(Suppl. 26):52–59.
   Google Scholar
• CARRETERO OA, SCICLI AG: The renal kallikrein-kinbi system. Am. J. Physiol. (1980) 238:F247–F255.
   PubMed Web of Science ®Google Scholar
• KAPLAN AP: Mechanisms of bradykinin generation in human plasma. Mon. Allergy (1983) 18:272–276.
   PubMedGoogle Scholar
• MAYFIELD RK, MARGOLIUS HS: Renal kallikrein-kinin system. Am. J. Nephrol. (1983) 3:145–155.
   PubMed Web of Science ®Google Scholar
• MILLS 111: Kallikreht kininogen and kinins in control of blood pressure. Nephron (1979) 23:61–71.
   PubMedGoogle Scholar
• MULLER-ESTERL W, IWANGA S, NAKANISHI S: Kininogens revisted. Trends Biochem. &I. 91986) 11:336-339. A thorough review of the kininogen family.
   Google Scholar
• FREY EK, KRAUT H, WERLE E, VOGEL R, ZICKGRAF-RUDEL G, TRAUTSCHOLD I: Das Kallikrein-Kinbi-System und seine Inhbitoren (1968) F Enke, Stuttgart.
   Google Scholar
• WERLE E, MAIER L: Ober die chemlsche tmd pharmak-ologische Unterscheidung von Kallikreinen ver-schiedener Herkunft. Biochem. Z. (1952) 323:279–288.
   PubMedGoogle Scholar
• PISANO JJ: Chemistry and biology of the k•Ilikrein-kinin system. In: Proteases and Biological Control (1975) Reich E, Rifkin DB, Shaw E (Eds), Cold Spring Harbour Lab.
   Google Scholar
• RABITO SF, SCICLI AG, CARRETERO OA: Immunoreactive glandular kallikrein in plasma. In: Enzymatic Release of Vasoactive Peptides (1980) Vogel GF (Ed), New York, Raven Press.
   Google Scholar
• GEIGER R, CLAUSNITZER B, FINK E, FRITZ H: Isolation of an enzymatically active glandular kallikrein from hu-man plasma by immunoaffinity chromatography. Hoppe Seylers Z. Physiol. Cbem. (1980) 361:1795–1803.
   PubMedGoogle Scholar
• CARRETERO OA, LUIS AC, SCICLI AG: The molecular biology of the kallikreln-kinin system: L General de-scription, nomenclature and the mouse gene family. Hypertension (1993) 11:693–697.
   Google Scholar
• A thorough reveiw of the latest investigations on the molecular biology of the kallikrein-kinin system.
   Google Scholar
• SPRAGG J, AUSTEN ICF: Plasma factors: The Hageman-factor-dependent pathways and the complement se-quence. In: Immunopharmacology (1977) Hadden JW, Coffey RG, Spreafico F (Eds), New York, Plenum Publishing Corp.
   Google Scholar
• SUNDSMO JS, FAIR DS: Relationships among the comple-ment kinin, coagulation and fibrinolytic systems in the inflammatory reaction. ain. Physiol. Biochem. (1983) 1:225–284.
   Web of Science ®Google Scholar
• VIO CP, LOYOLA S, VELARDE V: Localization of compo-nents of the kallikrein-kinin system in the kidney: relation to renal function. State of the art lecture. Hypertension (1992) 19\(Suppl. 2)1110–1116.
   Google Scholar
• NOLLY H, SCICLI AG, SCICLI G, CARRETERO MA: Charac-terization of a kininogenase from rat vascular tissue resembling tissue kallikrein. Circ. Res. (1985) 56:816–821.
   PubMed Web of Science ®Google Scholar
• NOLLY H, CARRATERO OA, SCICLI AG: Kallikrein release by vascular tissue. Am. J Physiol. (1993) 265 (Heart Circ. Physiol. 34):H1209–H1214.
   Google Scholar
• CHAO J, WOODLEY C, CHAO L, MARGOLIUS HS: Identifi-cation of tissue kallikrein in brain and in cell-free translation product encoded by brain mRNA. J. Biol. Chem. (1983) 258(24):15173–15178.
   PubMedGoogle Scholar
• SCHACHTER M, PERET MW, BILLING AG, WHEELER GD: Immunokalization of the protease kallikrein in the colon. J. Histochem. Cytochem. (1983) 31:1255–1260.
   PubMed Web of Science ®Google Scholar
• CHAO J, CHAO L, MARGOLIUS HS: Isolation of tissue k2Iiikrein in rat spleen by monoclonal antibody-affin-ity chromatography. Biochim. Biophys. Ada (1984) 801: 244–249.
   PubMed Web of Science ®Google Scholar
• SCICLI G, NOLLY H, CARREIERO OA, SCICLI AG: A Idni-nogenase resembling tissue kallikrein in adrenal glands. Kinin '87, Tokyo International Congress V (1987): Abstract.
   Google Scholar
• NUSTARD K, ORSTAVIK TB, GAUTVIK KM: Radioimmu-nological measurements of rat submandibular gland kallikrein (RSIE) in tissues and serum. Microvas. Res, (1987) 15(Abstr.):115–116.
   Google Scholar
• SEALEY JE, ATLAS ST, LARAGH JH, OZA NB, RYAN JW:Human urinary kallikrein converts inactive renin and Is a possible physiological activator of renin. Nature (1978) 275:144–145.
   PubMed Web of Science ®Google Scholar
• BARLAS A, OKAMOTO H, GREENBAUM LM: T-kininogen - the major plasma kinilnogen in rat adjuvant arthritis. Biochem. Biophys. Res. Commun. (1985) 129:280–286.
   PubMed Web of Science ®Google Scholar
• OKAMOTO H, GREENBAUM LM: Isolation and structure of T-kinin. Biochem. Biophys. Res. Commun (1983) 112 :701–708.
   PubMed Web of Science ®Google Scholar
• GIREY GJD, TALAMO RC, COLMAN RW: The kinetics of the release of bradykinin by kallikrein in normal hu-man plasma. J. Lab. Clin. Med. (1972) 80:496–507.
   PubMedGoogle Scholar
• TALAMO RC: Kinetics of kinin release and disappear-ance. In: Fogarty International Center Proceedings: Chemis-try and Biology of the Kallikrein-Kinin System in Health and Disease (1976) Pisano JJ, Austen KF (Eds).
   Google Scholar
• RYAN jw, ROBELERO J, STEWART JM: Inactivation of bradykinin in the pulmonary circulation. Biochem. J. (1968) 110:795–797.
   PubMed Web of Science ®Google Scholar
• ERDOS EG, YANG HYT: Kininases. In: Handbook of Experi-mental Pharmacology XXV (1979). Erdos EG (Ed), Berlin-Heidelberg-New York, Springer Verlag.
   Google Scholar
• SKIDGEL RA, SCHULZ WW, TAM LT, ERDOS EG: Human renal angiotensin I converting enzyme and neutral endopeptidase. Kidney Int. (1987) 20(Suppl.):S45–S46.
   Google Scholar
• URA N, CARRETERO OA, ERDOS EG: Role of renal en-dopeptidase 24.11 in kinin metabolism in vitro and its vivo. Kidney Int. (1987) 32:507–513.
   PubMed Web of Science ®Google Scholar
• ABELOUS JE, BARDIER E: Les substances hypotensives de l'urine humaine normale. C. R. Seances Soc. Biol. (1909) 66:511.
   Google Scholar
• FREY EK, KRAUT H: En neues Kreislaufhormon undseine Wirkung. Naunyn- Schmiedeberg's Arch. Exp. Patbol. Pharmakol. (1928) 133:1–56.
   Google Scholar
• BARBÉ J, MARCEAU F, THERIAULT B, DROUIN JN, REGOLI D: Cardiovascular actions of kinins in the rabbit. Can. J. Physiol. Pharmacol. (1979) 57:78–91.
   PubMed Web of Science ®Google Scholar
• MCCARTHY DA, POTTER DE, NICOLAIDES ED: Ants vivo estimation of the potencks and half-lives of synthetic bradykinin and Icallidin. j Pharmacol. Exp. Ther. (1965) 148:117–122.
   PubMed Web of Science ®Google Scholar
• LUCKHOFF A, BUSSE R, WINTER I, BASENGE E: Charac-terization of vascular relaxant factor released from cultured endothelial cells. Hypertension (1987) 9:295–303.
   PubMed Web of Science ®Google Scholar
• BUSSE R, FLEMING I: Kinin-mediated signal transduction In endothelial cells. In: ACE Inhibitors, Endothelial Func-tion and Artherosclerosis (1993). Schölkens BA, Unger T (Eds), Media Medica Publications Ltd.
   Google Scholar
• HILTON SM: The physiological role of glandular kallik-reins. Handb. Exp. Pharmacol (1970) 25:389–399.
   Google Scholar
• JAUCH KW, GUENTHER B, HARTL W, RETT K, WICKLMEYER M, DIETZE G: Improvement of impaired postoperative insulin action by bradykinin. BioL Chem. Hoppe-Seyler (1986) 367:207–210.
   PubMed Web of Science ®Google Scholar
• MARGOLIUS HS: Tissue kallikreins and kinins: Regula-tion and roles in hypertensive and diabetic diseases. Annu. Rev. Pharmacol. ToxicoL (1989) 29:343–364.
   PubMed Web of Science ®Google Scholar
• NASJLETTI A, MALIK KU: Renal kinin-prostaglandin re-lationship: implications for renal function. Kidney Int. (1981) 19:860–868.
   PubMed Web of Science ®Google Scholar
• COLLIER HOJ: Kinins and ventilation of the lungs. Handb. Exp. Pharmacol. (1970) 25:409–420.
   Google Scholar
• EISEN V: Formation and function of kinins. Rheumatol-ogy (1970) 3:103–168.
   Google Scholar
• KELLERMEYER RW, GRAHAM RC: Kinins - Possible physi-ologic and pathologic roles in man. New Engl. J. Med. (1968) 279:754–759, 802–807,859-866.
   Google Scholar
• BAUMGARTEN CR, LINZ W, ICUNKEL G, SCHOLICENS BA, WIEMER G: Rat increases bradykinin outflow from iso-lated rat hearts. Br. J. Pharmacol. (1993) 108:293-295. Detailed report on increased BK outflow during cardiac ischaemia in vitro.
   Google Scholar
• WlEMER G, SCHOLICENS BA, BECICER RHA, BUSSE R: Rat enhances endothelial autocoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hyper-tension (1991) 18:558–563.
   Google Scholar
• WEEMER G, SCHOLKENS BA, LINZ W: Endothelial protec-tion by converting enzyme inhibitors. Cardiovascular Res. (1994) In press.
   Google Scholar
• REGOLI D, BARABE J: Pharmacology of bradykinin and related kinins. Pharmacol. Rev. (1980) 32:1–46.
   PubMed Web of Science ®Google Scholar
• EMOND C, BASCANDS J-L, PECHER C, CABOS-BOUTOT G, PRADELLES P, REGOLI D, GIROLAMI J-P: Characterization of a B2-bradykinin receptor in rat renal mesangial cells. Eur. J. Pharmacol. (1990) 190:381–392.
   PubMed Web of Science ®Google Scholar
• MAECEAU F, REGOLI D: Mains receptors of the B2 type and their antagonists. In: Bradykinin Antagonists: Basic and Clinical Research (1991). Burch RM (Ed), New York: Marcel Dekker.
   Google Scholar
• VAVREK RJ, STEWART JM: Competitive antagonists of bradykinin. Peptides (1985) 6:161-164. First report of a highly selective B2 receptor antagonist.
   Google Scholar
• WAEBER B, AUBERT JF, VAVREK RJ, STEWART JM, NUSS-BERGER 3, BRUNNER HR: Role of bradykinin in blood pressure regulation of conscious spontaneously hyper-tensive rats. J. Hypertens. (1986) 4\(Suppl. 6):S597–S598.
   Google Scholar
• AUBERT JF, WAEBER B, NUSSBERGER J, VAVREK RJ, STE-WART JM, BRUNNER HR: Lack of a role of circulating bradykinin in the blood pressure response to acute angiotensin converting enzyme inhibition in rats. Agents Actions (1987) 22:349–354.
   PubMedGoogle Scholar
• MULINARI R, BENETOS A, GRAVAS I, GRAVAS H: Vascular and sympathoadrenal response to bradykinin and a bradykinin analogue. Hypertension (1988) 11:754–757.
   PubMed Web of Science ®Google Scholar
• HOCK FJ, WIRTH K, LINZ W, GERHARDS HJ, WIEMER G, HENKE ST, BREIPOHL G, KONIG W, KNOLLE J, SCHOLKENS BA: Hoe 140 a new potent and long acting bradykinin- antagonist.. In vitro studies. Br.J. PharmacoL (1991) 102:769–773.
   PubMed Web of Science ®Google Scholar
• Detailed report on icatibant as a very potent B2 receptor antagonist in vitro.
   Google Scholar
• WIRTH K, HOCK FJ, ALBUS U, LINZ W, ANAGNOSTOPOU- LOS H, HENKE ST, BREEPOHL G, KC:NIG W, KNOLLE J, SCHOLKENS BA: Hoe 140 a new potent and long acting bradykinin- antagonist In vivo studies. Br.J. PharmacoL (1991) 102:774–777.
   PubMed Web of Science ®Google Scholar
• Detailed report on icatibant as a very potent B2 receptor antagonist In vitro.
   Google Scholar
• GOHLKE P, LAMBERTY V, KUWER I, BARTENBACH 5, SCHNELL A, LINZ W, SCHOLKENS BA, WIEMER G, UNGER TH: Long-term low-dose angiotensin converting en-zyme inhibitor treatment increases vascular cyclic guanosine 3', S'-monophosphate. Hypertension (1993) 22:682–687.
   PubMed Web of Science ®Google Scholar
• BAO G, GOHLKE P, QUADRI F, UNGER TH: Chronic kinin receptor blockaile attenuates the antibrypertensive ef-fect of ramipriL Hypertension (1992) 20:74–79.
   Google Scholar
• KIFOR I, DZAU VJ: Endothelial re.nin-angiotensin path-way: Evidence for intracellular synthesis and secretion of angiotensin. Circ. Res. (1987) 60:422–428.
   Google Scholar
• YANAGISHAWA M, KURIEIARA H, KIMURA S, TOMBOE Y, KOBAYASHI M, MITSUI Y, GOTO K, MASAK T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (1988) 332:411–415.
   PubMed Web of Science ®Google Scholar
• MILNER P, KIRKPATRICK KA, RALEVIC V, TOOTHILL V, PEARSON J, BURNSTOCK G: Endothelial cells cultured from human umbilical vein release ATP, substance P, and acetylcholine in response to increased flow. Proc. R. Soc. Lond. (Biol) (1990) 241:245–248.
   PubMed Web of Science ®Google Scholar
• KAWASHIMA K, WATANABE N, OOHATA H, FUJIMOTO K, SUZUKI T, ISHIZAKI Y, MORITA I, MUROTA SI: Synthesis and release of acetylcholine by cultured bovine arterial endothelial cells. Neurosci. Lett. (1990) 119:156–158.
   PubMed Web of Science ®Google Scholar
• JOHNSON AR, SCHULZ WW, NOGUIERA, ERDOS EG: Kin-ins and angiotensins: Angiotensin I converting enzyme (kininase 11) in endothelial cells cultured from human pulmunaryarteries andveins. ClinHypertens. (1980)2:659–674.
   Web of Science ®Google Scholar
• SCHMAIER AH, KUO A, LUNDBERG D, MURRAY S, CINES DB: The expression of high molecular weight kinino-gen on human umbilical vein endothelial cells. J. Biol. Chem. (1988) 263:16327–16333.
   PubMed Web of Science ®Google Scholar
• SCHINI VB, BOULANGER C, REGOLI D, VANHOUTE PM: Bradykinin stimulates the production of cyclic GMP via activation of B2-kinin receptors in cultured porcine aortic endothelial cells. J. Pharmacol. Exp 7ber. (1990) 252:581–585.
   PubMed Web of Science ®Google Scholar
• DERIAN CK, MOSKOWITZ MA: Polyphosphoinositide hy-drolysis in endothelial cells and carotid segments (bradykinin-2 receptor stimulation is adcium-inde-pendent). J. Biol. Chem. (1986) 261:3831–3837.
   PubMed Web of Science ®Google Scholar
• LAMBERT TL, KENT RS, WHORTON AR: Bradykinin stimu-lation of inositol polyphosphate production in porcine aortic endothelial cells. J. Biol. Chem. (1986) 261:15288–15293.
   PubMedGoogle Scholar
• ADAMS DJ, BARAKEH J, LASKEY R, VAN BREMEN C: Ion channels and regulation of intracellular calcium in vascular endothelial calls. FASEB J. (1989) 3:2389–2400.
   PubMed Web of Science ®Google Scholar
• GABBIANI G, GLEMES G, GUELPA C, VALOTON MB, BADONNEL MC, HUTTNER I: Morphological and func-tional changes of the aortic intima during experimental hypertension. Am. J. Pathol. (1979) 96:399–426.
   PubMed Web of Science ®Google Scholar
• LeSCHER TF, VANHOUTTE PM, BOULANGER C, DOHI Y, BUHLER FR: Endothelial dysfunction in hypertension. In: Cardiovascular significance of endothelium-derived va-soactive factors (1991). Rubanyi G (Ed.). Futtua, New York.
   Google Scholar
• PANZA JA, QUYYUMIO AA, BRUSH JE, EPSTEIN SE: Abnor-mal endothelium-dependent vascular relaxation in pa-tients with essential hypertension. N. Engl.J. Med. (1990) 323:22–27.
   PubMed Web of Science ®Google Scholar
• LINDER L, KIOWSKI W, BOBLER FR, LOSCHER TF: Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response to essential hypertension. Circulation (1990) 81:1762–1767.
   PubMed Web of Science ®Google Scholar
• MESSERLI FH, ICETELHUT R: Left ventricular hypertro-phy: an independent risk factor.]. Cardiovasc. Pharma-col. (1991) 17\(Suppl. 4):59–67.
   Google Scholar
• ROSAS R, MONTAGUE D, GROSS M, BOHR DF: Cardiac action of vasoactive polypeptides in the rat. I. Braclykinin. LL Angiotensin. Circ. Res. (1965) 16:150–161.
   PubMedGoogle Scholar
• NAKASHIMA A, ANGUS JA, JOHNSTON CI: Chronotropic effects of angiotensin I, angiotensin U, bradykinin, and norepinephrine in guinea pig atria. Eur. J Pharmacol (1982) 81:479–485.
   PubMed Web of Science ®Google Scholar
• KOCH-WESER J: Myocardial action of angiotensin. Circ. Res. (1964) 14:337–344
   PubMed Web of Science ®Google Scholar
• ERTL G: Angiotensin converting enzyme inhibitors and ischernic heart disease. Eur. Heart. J. (1988) 9:716–727.
   PubMed Web of Science ®Google Scholar
• LINZ W, SCHOLKENS BA, HAN YF: Beneficial effects of the converting enzyme inhibitor ramipril in ischemic hearts. J. Cardiovasc. PbarmacoL (1986) 8\(Suppl. 10):591–S99.
   Google Scholar
• LINZ W, SCHOLKENS BA: Influence of local converting enzyme inhibition on angiotensin and bradykinin ef-fects in ischemic rat hearts. J. Cardiovasc. Pharmacol (1987) 10\(Suppl. 7):S75–S82
   Google Scholar
• SCHELLING P, GANTEN D, SPECK G, FISCHER H: Effects of angiotensin.11 and angiotensin II antagonist saralasin on cell growth and renin in 3T3 and SV313 cells. J. Cell. Physiol. (1979) 98:503–513.
   Google Scholar
• PAQUET JL, BANDOMIN-LEGROS M, BRUNELLE G, MEYER P: Angiotensin 11-induced proliferation of aortic myo-cytes in spontaneously hypertensive rats. J. Hypertens. (1990) 8:565–572.
   PubMed Web of Science ®Google Scholar
• GEISTERFER ART, PEACH MJ, OWENS GK: Angiotensin 11 Induces hypertrophy not hyperplasia of cultured rat aortic smooth muscle cells. Circ. Res. (1988) 62:749–756.
   PubMed Web of Science ®Google Scholar
• FREEMAN GL, LITTLE WC, HAYWOOD JR: Reduction ofleft ventricular mass in normal rats by captopriL Cardiovasc. Res. (1987) 21:323–327.
   Google Scholar
• FERNANDEZ PG, SNEDDEN W, IDIKI0 H, FERNANDEZ D,KIN BK, TRIGGLE CR: The reversal of left ventricular hypertrophy with control of blood pressure in experi-mental hypertension. Scand. J. Clin. Lab. Invest. (1984) 44:711–716.
   PubMed Web of Science ®Google Scholar
• CLOZEL JP, HEFTI F: CiLizapril prevents the develop-ment of cardiac hypertrophy and the decrease in coro-nary reserve in spontaneously hypertensive rats. Cardiovasc. Pharmacol. (1988) 11:568–572.
   PubMed Web of Science ®Google Scholar
• BRILLA CG, JANICKI JS, WEBER KT: Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation (1991) 83:1771–1779.
   PubMed Web of Science ®Google Scholar
• CHILDS TJ, ADAMS MA, MAK AS: Regression of cardiac hypertrophy in spontaneously hypertensive rats by enalapril and the expression of contractile proteins. Hypertension (1990) 16:662–668.
   PubMed Web of Science ®Google Scholar
• NAKASHIMA Y, FOUAD FM, TARAZI RC: Regression of left ventricular hypertrophy from systemic hypertension by enalapriL Am. J. CardioL (1984) 53:1044–1049.
   Web of Science ®Google Scholar
• LINZ W, SCHOLICENS BA, GANTEN D: Converting enzyme inhibition specifically prevents the development and Induces regression of cardiac hypertrophy in rats. Clin. E. Hypertens-Theory Pract. (1989) A11(7):267–275.
   Google Scholar
• Detailed report on regression of left ventricle hypertrophy after treatment with a subantihypertensive dose of ramipril.
   Google Scholar
• LIEVRE M, GUERET P, DELAIR 5, BOISSEL JP, on behalf of the Hycar study: ACE- inhibitor-induced reduction in left ventricular mass independent of changes in blood pressure in hypertensive patients with left ventricular hypertrophy. Hypertension (1993) 22:417.
   Google Scholar
• CLOZEL JP, KUHN H, HEFTI F: Effects of chronic ACE Inhibition on cardiac hypertrophy and coronary vas-cular reserve in spontaneously hypertensive rats with developed hypertension. J. Hypertens. (1989) 7:267–275.
   PubMed Web of Science ®Google Scholar
• ODORI T, PASKINS-HURLBURT A, HOLLENBERG NK: In-crease in collateral arterial endothelial cell prolifera-tion induced by captopril after renal artery stenosis in the rat. Hypertension (1983) 5:307–311.
   PubMed Web of Science ®Google Scholar
• CRISMAN RP, RITrMANN B, TOMANEK RJ: Exercise-in-duced myocardial growth in the spontaneously hyper-tensive rat. Microvasc. Res. (1985) 30:185–194.
   PubMed Web of Science ®Google Scholar
• FULTON WFM, THOMAS CC: The coronary arteries (1965) Thomas CC (Ed), Springer field, 11.
   Google Scholar
• GOTTW11( M, PUSCHMANN S, WUESTEN B, NIENABER C, MOLLER ICD, HOFMANN M, SCHAPER W: Myocardial pro-tection by collateral vessels during experimental coro-nary ligation. A prospective study in a canine two-infarct modeL Basic Res. Cardiol. (1984) 79:337–343.
   PubMedGoogle Scholar
• TOMANEK RJ, WESSEL TJ, HARRISON DG: Capillary growth and geometry during long-term hypertension and myocardial hypertrophy in dogs. Am. j Physiol. (1991) 261:H1011–H1018.
   PubMed Web of Science ®Google Scholar
• TOMANEK RJ, HOVANEC JM: The effects of long-term pressure-overload and aging in the myocardhun. J. Mol. Cell. Cardiol. (1981) 13:471–488.
   PubMed Web of Science ®Google Scholar
• MESSERLI FH, KFTELHUT R: Left ventricular hypertro-phy: an independent risk factor. J. Cardiovasc. Pharma-col. (1991) 17\(Suppl. 4):59–67.
   Google Scholar
• SCHAPER W, DEBRABANDER M, LEWI P: DNA synthesis and mitosis in coronary collateral vessels of the dog. Circ. Res. (1971) 28:671–679.
   PubMed Web of Science ®Google Scholar
• MEINIGER C, GRANGER H: Mechanisms leading to adeno-sine-stimulated proliferation of microvascular endo-thelial cells. Am.J. Physiol. (1990) 258:H198–H206.
   PubMed Web of Science ®Google Scholar
• QUINKLER W, MAASBERG M, BERNOTAT-DANIELOWSKI S, LUTHE N, SHARMA HS, SCHAPER W: Isolation of hepa-rin-binding growth factors from bovine, porcine and canine hearts. Eur. J. Biocbem. (1989) 181:67–73.
   PubMedGoogle Scholar
• ROBERTS AB, SPORN MB, ASSOIAN RK, SMITH JM, ROCHE NS, WAKEFIELD L, HEINE V, LIOTTA L, FALANGA V, ICEHR JH, FAUCI AS: Transforming growth factor type-beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc. Natl. Res. Comm. USA (1986) 83:4167–4171.
   PubMed Web of Science ®Google Scholar
• CASSCELLS W, SPEIR E, SASSE J, KLAGSBRUN M, ALLEN P, LEE M, CALVO B, CHIBA M, HAGGROTH L, FOLKMAN J, EPSTEIN S: Isolation, characterization, and localization of heparin-binding growth factors in the heart. j Clin. Invest. (1990) 85:433–441.
   PubMed Web of Science ®Google Scholar
• ADAIR T, GAY WJ, MONTANI JP: Growth regulation of the vascular system: evidence for a metabolic hypothesis. Am. J. Physiol. (1990) 259:R393–R404.
   PubMed Web of Science ®Google Scholar
• LINZ W, MARTORANA PA, SCHOLKENS BA: Local inhibi-tion of bradykinin degradation in ischemic hearts. J. Cardiovasc. Pharmacol. (1990) 13:99–109.
   Google Scholar
• ROSEN P, EC10EL J, REINALTER H: Influence of bradykituln on glucose uptake and metabolism studies in isolated cardiac myocytes and isolated perfused hearts. Physiol. Chem. (1983) 364:431–438.
   Google Scholar
• METSARINNE ICP, STOLL M, GOHLKE P, PAUL M, UNGER TH: Angiotensin II is antiproliferative for coronary endothelial cells in vitro. Pbarm. Pharmacol. Lett. (1992) 2:150–152.
   Google Scholar
• STOLE M, STECKELINGS UM, BOTTARI SP, UNGER T: Regulation of endothelial cell growth: Role of the angiotensin II AT2-receptor. Circulation (1993) 88\(Suppl. 4):I–469.
   Google Scholar
• STOLE M, LAMBERTY V, GOHLKE P, METSARINNE ICP, UNGER T: Capillary growth induced by ACE inhibitors:
   Google Scholar
• In vivo and in vitro studies. In: ACE InEndothelialFunction and Artberosclerosfs (1993). Schölkens BA, Unger T (Eds), Media Medica Publications Ltd.
   Google Scholar
• MOB1DELLI L, PARENTI A, GRANGER HJ, ZICHE M, LEDDA F: Activation of DNA synthesis and inositol-phosphate turnover in coronaryvenular endothelial cells exposed to bradykinin. Pharmacological Research (1993) 25\(Suppl. 2):150–151.
   Google Scholar